22 patents currently held
38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in May 2034. from the record
Of the 38 now held by other companies, 32 name Regeneron Pharmaceuticals Inc. as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2034
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2036 · High confidence
Also notable
Ends Jun 2035 · High confidence
Also notable
Ends no later than Apr 2035 · Medium confidence
Bcma Chimeric Antigen Receptors
US 10,383,929
Cited by 54 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2036.
Methods of Making T Cell Compositions
US 10,479,975
Cited by 60 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2035.
MND Promoter Chimeric Antigen Receptors
US 10,774,343
Cited by 44 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends no later than Jul 2034 · Medium confidence
Cited by 53 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Regeneron Pharmaceuticals, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Bcma Chimeric Antigen Receptors (US 10,383,929) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due May 19, 2027The maintenance fee for Methods of Making T Cell Compositions (US 10,479,975) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Bcma Chimeric Antigen Receptors (US 10,624,960) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
- 3 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
What they patent
The 5 largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bcma Chimeric Antigen Receptors | 10 in force | to Feb 2036 |
| Methods of Making T Cell Compositions | 3 in force | to Mar 2037 |
| Anti-Bcma Car Antibodies, Conjugates, and Methods of Use (2022) | 1 in force | to May 2043 |
| Anti-Bcma Car Antibodies, Conjugates, and Methods of Use (2020) | 1 in force | to Jul 2042 |
| Anti-Bcma Car T Cell Compositions | 1 in force | to Jun 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,000,746 | A Laglidadg Homing Endonuclease Cleaving the T Cell Receptor Alpha Gene and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,006,052 | A Laglidadg Homing Endonuclease Cleaving the C-C Chemokine Receptor TYPE-5 (CCR5) Gene and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,774,343 | MND Promoter Chimeric Antigen Receptors In force · Medium confidence | In force | Medium confidence | |
| US 12,291,722 | Improved Methods for Manufacturing Adoptive Cell Therapies In force · High confidence | In force | High confidence | |
| US 10,479,975 | Methods of Making T Cell Compositions In force · High confidence | In force | High confidence | |
| US 11,479,755 | T Cell Compositions In force · High confidence | In force | High confidence | |
| US 12,644,099 | Methods for Making T Cell Compositions In force · Medium confidence | In force | Medium confidence | |
| US 10,624,960 | Bcma Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 10,639,358 | Bcma Chimeric Antigen Receptors In force · High confidence | In force | High confidence | |
| US 10,639,359 | Bcma Chimeric Antigen Receptors In force · High confidence | In force | High confidence |
Also on record, not counted in the 22: 38 patents in force now held by others · 15 applications pending · 22 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.